---
title: "Preregistration (science)"
chunk: 2/4
source: "https://en.wikipedia.org/wiki/Preregistration_(science)"
category: "reference"
tags: "science, encyclopedia"
date_saved: "2026-05-05T03:50:00.803493+00:00"
instance: "kb-cron"
---

=== Creation and development ===
For many years, scientists and others have worried about reporting biases such that negative or null results from initiated clinical trials may be less likely to be published than positive results, thus skewing the literature and our understanding of how well interventions work. This worry has been international and written about for over 50 years.  One of the proposals to address this potential bias was a comprehensive register of initiated clinical trials that would inform the public which trials had been started. Ethical issues were those that seemed to interest the public most, as trialists (including those with potential commercial gain) benefited from those who enrolled in trials, but were not required to "give back," telling the public what they had learned.
Those who were particularly concerned by the double standard were systematic reviewers, those who summarize what is known from clinical trials.  If the literature is skewed, then the results of a systematic review are also likely to be skewed, possibly favoring the test intervention when in fact the accumulated data do not show this, if all data were made public.
ClinicalTrials.gov was originally developed largely as a result of breast cancer consumer lobbying, which led to authorizing language in the FDA Modernization Act of 1997 (Food and Drug Administration Modernization Act of 1997.  Pub L No. 105-115, §113 Stat 2296), but the law provided neither funding nor a mechanism of enforcement.  In addition, the law required that ClinicalTrials.gov only include trials of serious and life-threatening diseases.
Then, two events occurred in 2004 that increased public awareness of the problems of reporting bias.  First, the then-New York State Attorney General Eliot Spitzer sued GlaxoSmithKline (GSK) because they had failed to reveal results from trials showing that certain antidepressants might be harmful.
Shortly thereafter, the International Committee of Medical Journal Editors (ICMJE) announced that their journals would not publish reports of trials unless they had been registered.  The ICMJE action was probably the most important motivator for trial registration, as investigators wanted to reserve the possibility that they could publish their results in prestigious journals, should they want to.
In 2007, the Food and Drug Administration Amendments Act of 2007 (FDAAA) clarified the requirements for registration and also set penalties for non-compliance (Public Law 110-85. The Food and Drug Administration Amendments Act of 2007  [1].

=== International participation ===
The International Committee of Medical Journal Editors (ICMJE) decided that from July 1, 2005 no trials will be considered for publication unless they are included on a clinical trials registry.  The World Health Organization has begun the push for clinical trial registration with the initiation of the International Clinical Trials Registry Platform. There has also been action from the pharmaceutical industry, which released plans to make clinical trial data more transparent and publicly available. Released in October 2008, the revised Declaration of Helsinki, states that "Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject."
The World Health Organization maintains an international registry portal at https://apps.who.int/trialsearch/. WHO states that the international registry's mission is "to ensure that a complete view of research is accessible to all those involved in health care decision making. This will improve research transparency and will ultimately strengthen the validity and value of the scientific evidence base."
Since 2007, the International Committee of Medical Journal Editors ICMJE accepts all primary registries in the WHO network in addition to clinicaltrials.gov. Clinical trial registration in other registries excluding ClinicalTrials.gov has increased irrespective of study designs since 2014.

=== Reporting compliance ===
Various studies have measured the extent to which various trials are in compliance with the reporting standards of their registry.

=== Overview of clinical trial registries ===

Worldwide, there is growing number of registries. A 2013 study identified the following top five registries (numbers updated as of August 2013):

=== Overview of preclinical study registries ===
Similar to clinical research, preregistration can help to improve transparency and quality of research data in preclinical research. In contrast to clinical research where preregistration is mandatory for vast parts it is still new in preclinical research. A large part of preclinical and basic biomedical research relies on animal experiments. The non-publication of results gained from animal experiments not only distorts the state of research by reinforcing the publication bias, it further represents an ethical issue. Preregistration is discussed as a measure that could counteract this problem. Following registries are suited for the preregistration of preclinical studies.

== Journal support ==
Over 200 journals offer a registered reports option (Centre for Open Science, 2019), and the number of journals that are adopting registered reports is approximately doubling each year (Chambers et al., 2019).
Psychological Science has encouraged the preregistration of studies and the reporting of effect sizes and confidence intervals. The editor-in-chief also noted that the editorial staff will be asking for replication of studies with surprising findings from examinations using small sample sizes before allowing the manuscripts to be published.
Nature Human Behaviour has adopted the registered report format, as it "shift[s] the emphasis from the results of research to the questions that guide the research and the methods used to answer them".
European Journal of Personality defines this format: "In a registered report, authors create a study proposal that includes theoretical and empirical background, research questions/hypotheses, and pilot data (if available). Upon submission, this proposal will then be reviewed prior to data collection, and if accepted, the paper resulting from this peer-reviewed procedure will be published, regardless of the study outcomes."
Note that only a very small proportion of academic journals in psychology and neurosciences explicitly stated that they welcome submissions of replication studies in their aim and scope or instructions to authors. This phenomenon does not encourage the reporting or even attempt on replication studies.
Overall, the number of participating journals is increasing, as indicated by the Center for Open Science, which maintains a list of journals encouraging the submission of registered reports.